enVVeno Medical Corp (NVNO) Spending and interest coverage
- R&D / revenue · 12 months: Value (m); Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value (m); Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | (m) | Research and development expense / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Stock-based compensation / revenue · 12 months | (m) | Share-based compensation / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 8.72M USD | Research and Development Expense |
| Revenue | (m) | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 2.19M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -16.75M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $8.72M | (m) | $2.19M | $-16.75M | (m) | (m) | (m) | (m) | (m) |
| 2026-03-31 | $9.54M | (m) | $3.24M | $-20.01M | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | $9.98M | (m) | $3.42M | $-20.90M | (m) | (m) | (m) | (m) | (m) |
| 2025-09-30 | $11.55M | (m) | $3.80M | $-23.59M | (m) | (m) | (m) | (m) | (m) |
| 2025-06-30 | $11.82M | (m) | $4.12M | $-24.87M | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | $11.75M | (m) | $3.68M | $-23.28M | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | $12.25M | (m) | $4.14M | $-23.83M | (m) | (m) | (m) | (m) | (m) |
| 2024-09-30 | $11.72M | (m) | $4.27M | $-23.41M | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | $11.65M | (m) | $4.37M | $-22.58M | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | $13.04M | (m) | $4.52M | $-23.94M | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | $13.58M | (m) | $5.20M | $-25.24M | (m) | (m) | (m) | (m) | (m) |
| 2023-09-30 | $13.40M | (m) | $6.29M | $-25.42M | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | $13.10M | (m) | $7.40M | $-26.22M | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | $11.96M | (m) | $8.54M | $-26.39M | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | $9.91M | (m) | $8.99M | $-24.93M | (m) | (m) | (m) | (m) | (m) |
| 2022-09-30 | $8.90M | (m) | $12.10M | $-27.46M | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | $7.63M | (m) | $10.15M | $-24.02M | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | $5.65M | (m) | $8.11M | $-19.42M | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | $5.73M | (m) | $6.00M | $-16.89M | (m) | (m) | (m) | (m) | (m) |
| 2021-09-30 | $6.22M | (m) | $986.37K | $-12.06M | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | $5.76M | (m) | $855.78K | $-11.27M | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | $5.37M | (m) | $691.38K | $-10.43M | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $4.25M | (m) | $693.11K | $-9.14M | (m) | (m) | (m) | (m) | (m) |
| 2020-09-30 | $2.76M | (m) | $559.72K | $-7.28M | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | $2.68M | (m) | $559.23K | $-7.19M | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | $2.40M | (m) | $968.54K | $-7.60M | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | $2.21M | $31.24K | $941.96K | $-7.68M | (m) | 7061.17% | 3014.95% | (m) | (m) |
| 2019-09-30 | $1.71M | $61.70K | $1.02M | $-7.18M | (m) | 2773.74% | 1654.51% | (m) | (m) |
| 2019-06-30 | $1.46M | $103.37K | $1.21M | $-6.83M | (m) | 1411.63% | 1175.11% | (m) | (m) |
| 2019-03-31 | $1.31M | $186.73K | $1.89M | $-7.98M | (m) | 702.23% | 1011.83% | (m) | (m) |
| 2018-12-31 | $1.24M | $186.55K | $1.92M | $-7.85M | (m) | 664.02% | 1030.52% | (m) | (m) |
| 2018-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | $649.74K | $422.11K | $878.40K | $-6.10M | (m) | 153.93% | 208.10% | (m) | (m) |
| 2017-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sonoma Pharmaceuticals, Inc. (SNOA) | United States | $0.006B | -2.59 |
| Co-Diagnostics, Inc. (CODX) | United States | $0.007B | -0.32 |
| INTELLIGENT BIO SOLUTIONS INC. (INBS) | United States | $0.005B | |
| AETHLON MEDICAL INC (AEMD) | United States | $0.005B | |
| Bluejay Diagnostics, Inc. (BJDX) | United States | $0.004B | |
| OSR Health, Inc. (OSRH) | United States | $0.004B | -0.75 |
| Adagio Medical Holdings, Inc. (ADGM) | United States | $0.004B | |
| Autonomix Medical, Inc. (AMIX) | United States | $0.004B | |
| Beyond Air, Inc. (XAIR) | United States | $0.003B | -0.01 |
| Vivos Therapeutics, Inc. (VVOS) | United States | $0.003B | -0.26 |